New Considerations for the Treatment of Glioblastoma Multiforme: Evaluating the Potential for Immune Checkpoint Inhibitors
The content for this activity is based on the satellite symposium, “New Considerations for the Treatment of Glioblastoma Multiforme: Evaluating the Potential for Immune Checkpoint Inhibitors”, that was presented at the 21st Annual Meeting of the Society for Neuro-Oncology in Scottsdale, Arizona on November 17, 2016. Glioblastoma multiforme (GBM) remains one of the most feared of all malignancies due to its aggressive nature and correspondingly low survival rates. Recently, immunotherapies – particularly immune checkpoint inhibitors – have shown promise in treating patients with GBM in cases where conventional treatment options have failed. This archived symposium activity will provide participants with the opportunity to optimize the diagnosis and management of patients with GBM, including new data and remaining challenges resulting from recent clinical trials in the use of immune checkpoint inhibitors.
This enduring activity is intended for neuro-oncologists, neurosurgeons, neuropathologists, radiology and medical oncologists in the US, Canada, and Europe, as well as nurse practitioners, physician assistants, oncology nurses, and clinical oncology pharmacists. No prerequisites required.
Upon completion of this activity, participants will be better able to do the following:
- DESCRIBE the latest evidence providing rationale for targeting the immune system in the treatment of GBM.
- EVALUATE results of ongoing clinical trials examining immunotherapy agents as part of GBM treatment paradigms.
- RECOGNIZE strategies to manage the unique adverse events related to the use of immunotherapy in GBM.
Michael Lim, MD (Chair)
David A. Reardon, MD
John H. Sampson, MD, PhD, MBA
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter
Relationship Identified With:
Michael Lim, MD
Consultant/Advisor: Agenus Inc; Bristol-Myers Squibb Company; Merck & Co., Inc.; Oncorus; Regeneron
Grant/Research Support: Accuray Incorporated; Agenus Inc; Bristol-Myers Squibb Company; ImmunoCellular Therapeutics, Ltd.
David A. Reardon, MD
Speakers’ Bureau: Bristol-Myers Squibb Company; Genentech, Inc.; Inovio Pharmaceuticals, Inc.; Juno Therapeutics; Merck & Co., Inc.; Momenta Pharmaceuticals; Novartis AG; Regeneron
Consultant/Advisor: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Cavion; Celldex Therapeutics; EMD Serono, Inc.; Genentech, Inc.; Inovio Pharmaceuticals; Juno Therapeutics; Mateon Therapeutics, Inc.; Merck & Co., Inc.; Midatech Pharma PLC; Momenta Pharmaceuticals; Novartis AG; Novocure; Regeneron; Stemline Therapeutics, Inc.
Grant/Research Support: Celldex Therapeutics; Incyte Corporation; Midatech Pharma PLC
John H. Sampson, MD, PhD, MBA
Has no financial relationships to disclose
Non-faculty: Daniel Guinee; Christina M. Ohnsman, MD;Sandy Breslow; Alison Kemp; Leah Johnson and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Bristol-Myers Squibb Company.
Jointly provided by the Elsevier Office of Continuing Medical Education and ASiM.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits.TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at email@example.com.
Canadian physicians can claim MOC section 2 credit for this activity by logging into your MAINPORT ePortfolio account and claiming the activity as appropriate for Section 2 self-learning. For questions, please go to www.royalcollege.ca/rcsite/cpd/maintenance-of-certification-program-e.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM, and Bristol-Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.50 AMA PRA Category 1 Credit(s)™
- 1.50 Non-physician